| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10596804 | Bioorganic & Medicinal Chemistry Letters | 2010 | 5 Pages |
Abstract
A series of spiro-azetidines and azetidinones has been evaluated as novel blockers of the T-type calcium channel (CaV3.2) which is a new therapeutic target for the potential treatment of both inflammatory and neuropathic pain. Confirmation and optimization of the potency, selectivity and DMPK properties of leads will be described.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Elizabeth M. Smith, Steve Sorota, Hyunjin M. Kim, Brian A. McKittrick, Terry L. Nechuta, Chad Bennett, Chad Knutson, Duane A. Burnett, Jane Kieselgof, Zheng Tan, Diane Rindgen, Terry Bridal, Xiaoping Zhou, Yu-Ping Jia, Zoe Dong, Debbie Mullins,